Fresenius SE & Co. KGaA FRE.DE
Composite 56/100; the shares have moved about 25% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 45/100 — a slight mark against it.
Valuation ranks 72/100 — a moderate point in its favour. Income ranks 67/100 — a moderate point in its favour. Growth ranks 66/100 — a moderate point in its favour.
Quality ranks 45/100 — a slight mark against it. Momentum ranks 48/100 — a slight mark against it. Balance-sheet strength ranks 50/100 — a slight mark against it.
What the company does Fresenius SE & Co. KGaA operates through two segments: Fresenius Kabi (critical and chronic care products) and Fresenius Helios (hospitals and medical centers). Its portfolio includes biopharmaceuticals, clinical nutrition, IV fluids, and hospital information systems.
Key financials ROE 8%, ROA 3%, ROCE 8%; gross/operating/net margins 25%/10%/6%. Revenue growth 2%, EPS growth 90%. Debt/Equity 0.58, net debt/EBITDA 3.25, interest coverage 7.8x, current ratio 1.26.
Stock health SiderAva scores: Overall 55 (weak quality, attractively valued), Quality 44, Growth 59, Valuation 73, Momentum 46, Income 74. Piotroski F-Score 8/9, Altman Z 2.0. Dividend yield 2%, payout 37%.
Price vs fair value The stock trades at a **discount** of 29% to our fair-value estimate (58 vs 45) and a **discount** of 22% to the 12-month target (55 vs 45). - Trading at a discount despite 66% run (Simply Wall St.) - Peer earnings beats (Chemed, Ensign) may pressure relative multiples (Zacks) - Valuation percentile 73 (top quartile) supports attractiveness (SiderAva)
Looking forward Forward P/E 13x, PEG 0.4x, EV/EBITDA 9x. Analysts see 22% upside to 55 over 12 months (14 analysts). Growth remains modest (2% revenue) but margins and ROE are improving.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.